Santhera Revenue Surges
Santhera Pharmaceuticals reports doubling first-half revenue and narrowing losses amid strong drug sales.
Anonymous
Key Points
1
Santhera said royalties and milestone income totaled CHF 29.1 million, largely reflecting Nxera’s $30 million upfront payment as well as payments from Catalyst and Sperogenix.
2
Operating expenses fell 8.4% to CHF 25 million, and the operating loss narrowed to CHF 6.6 million from CHF 35.4 million a year earlier, partly because postmarketing studies were completed and development spending declined.
3
AGAMREE had launched in Germany, the U.K., Spain and Italy, as well as Austria and Luxembourg; Spain and Italy had secured national pricing and reimbursement, and Poland had also joined the reimbursed markets.
4
Basic and diluted loss per share from continuing operations improved to CHF 1.50 from CHF 3.04 in the first half of 2025.
Santhera Pharmaceuticals doubled its first-half revenue to CHF 48.33 million, up from CHF 24.01 million a year earlier, as its DMD treatment AGAMREE gained traction across European markets TipRanks. The Swiss drugmaker's net loss narrowed sharply to CHF 21.53 million from CHF 38.83 million, signaling a shift toward profitability as the company cut costs and ramped up commercial operations.
AGAMREE Expansion Drives Sales Growth
AGAMREE product sales jumped to CHF 19.23 million in the first half, powering overall revenue gains Investing.com. The Duchenne muscular dystrophy drug launched in Germany, the U.K., Spain, Italy, Austria, and Luxembourg. Spain, Italy, and Poland secured reimbursement, clearing a major hurdle for patient access and steady revenue streams.
Licensing Deals and Milestone Payments Boost Top Line
Royalties and milestone income totaled CHF 29.1 million, largely from Nxera's CHF 30 million upfront payment plus payments from Catalyst and Sperogenix Goldea Capital. These deals cushioned the company's finances while AGAMREE ramped up globally. The licensing revenue masked slower-than-expected early AGAMREE sales and helped offset ongoing losses.
Operating Costs Fall, Path to Breakeven Clears
Operating expenses fell 8.4% to CHF 25 million as postmarketing studies wrapped and development spending declined Yahoo Finance. The operating loss narrowed to CHF 6.6 million from CHF 35.4 million a year earlier. Management said cash is sufficient for near-term needs and expects the company to return to cash generation in the second half of 2027.
Risks Ahead: German Price Cuts and Reimbursement Delays
Management flagged potential headwinds, including German price cuts and delays in securing reimbursement in key markets Seeking Alpha. Loss per share improved to CHF 1.50 from CHF 3.04 in the prior-year period, but execution risks remain. If AGAMREE uptake stalls or reimbursement talks drag, the path to profitability could lengthen.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
48
Reach
60
Topics
A
AnonymousAuthor
